Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawinskiego 5a, 02-106 Warsaw, Poland.
Biological and Chemical Research Centre, University of Warsaw, Żwirki i Wigury 101, 02-089 Warsaw, Poland.
Molecules. 2021 Feb 3;26(4):794. doi: 10.3390/molecules26040794.
Phosphodiesterase 5 (PDE5) is one of the most extensively studied phosphodiesterases that is highly specific for cyclic-GMP hydrolysis. PDE5 became a target for drug development based on its efficacy for treatment of erectile dysfunction. In the present study, we synthesized four novel analogues of the phosphodiesterase type 5 (PDE5) inhibitor-tadalafil, which differs in (i) ligand flexibility (rigid structure of tadalafil vs. conformational flexibility of newly synthesized compounds), (ii) stereochemistry associated with applied amino acid building blocks, and (iii) substitution with bromine atom in the piperonyl moiety. For both the intermediate and final compounds as well as for the parent molecule, we have established the crystal structures and performed a detailed analysis of their structural features. The initial screening of the cytotoxic effect on 16 different human cancer and non-cancer derived cell lines revealed that in most cases, the parent compound exhibited a stronger cytotoxic effect than new derivatives, except for two cell lines: HEK 293T (derived from a normal embryonic kidney, that expresses a mutant version of SV40 large T antigen) and MCF7 (breast adenocarcinoma). Two independent studies on the inhibition of PDE5 activity, based on both pure enzyme assay and modulation of the release of nitric oxide from platelets under the influence of tadalafil and its analogues revealed that, unlike a reference compound that showed strong PDE5 inhibitory activity, the newly obtained compounds did not have a noticeable effect on PDE5 activity in the range of concentrations tested. Finally, we performed an investigation of the toxicological effect of synthesized compounds on in the highest applied concentration of and (160 μM) and did not find any effect that would suggest disturbance to the life cycle of . The lack of toxicity observed in and enhanced, strengthened selectivity and activity toward the MCF7 cell line made good leading structures for further structure activity optimization and makes a reasonable starting point for the search of new, selective cytotoxic agents.
磷酸二酯酶 5(PDE5)是研究最广泛的磷酸二酯酶之一,对环鸟苷酸水解具有高度特异性。基于其治疗勃起功能障碍的功效,PDE5 成为药物开发的靶点。在本研究中,我们合成了磷酸二酯酶 5(PDE5)抑制剂他达拉非的四个新型类似物,这些类似物在以下方面有所不同:(i)配体的柔韧性(他达拉非的刚性结构与新合成化合物的构象柔韧性);(ii)与应用的氨基酸构建块相关的立体化学;以及(iii)在哌啶基部分用溴原子取代。我们确定了中间产物和最终产物以及母体分子的晶体结构,并对其结构特征进行了详细分析。对 16 种不同的人类癌症和非癌症来源的细胞系进行的细胞毒性作用的初步筛选表明,在大多数情况下,母体化合物比新衍生物表现出更强的细胞毒性作用,但有两种细胞系除外:HEK 293T(来源于正常胚胎肾,表达 SV40 大 T 抗原的突变体)和 MCF7(乳腺腺癌)。两项基于纯酶测定和在他达拉非及其类似物的影响下调节血小板中一氧化氮释放的 PDE5 活性抑制的独立研究表明,与显示出强 PDE5 抑制活性的参考化合物不同,新获得的化合物在测试浓度范围内对 PDE5 活性没有明显影响。最后,我们在最高应用浓度(160 μM)下研究了合成化合物的毒性作用,没有发现任何表明对 生命周期有干扰的作用。在 和 中观察到缺乏毒性作用,并增强了对 MCF7 细胞系的选择性和活性,这使得 成为进一步结构活性优化的良好先导结构,并为寻找新的、选择性细胞毒性剂提供了合理的起点。